ArticleOncogene2000
Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 78 citations in OpenAlex.
- Rb substantially compensates for the double loss of p130 and p107 in adult but not embryonic neural stem cell lineages.Cell death & disease · 2025Article
- The role of alternative pre-mRNA splicing in cancer progression.Cancer cell international · 2023Review
- Emerging Role of E2F Family in Cancer Stem Cells.Frontiers in oncology · 2021Review
- Transcription Factor E2F3a in Nucleus Accumbens Affects Cocaine Action via Transcription and Alternative Splicing.Biological psychiatry · 2018Article
- Transcription factor E2F3a regulatesCancer cell international · 2018Article
- MicroRNA-17-92 Regulates the Transcription Factor E2F3b during Myogenesis In Vitro and In Vivo.International journal of molecular sciences · 2017Article
- MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.Oxidative medicine and cellular longevity · 2017Article
- Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Tissue-specific targeting of cell fate regulatory genes by E2f factors.Cell death and differentiation · 2016Article
- E2F1 and E2F2 induction in response to DNA damage preserves genomic stability in neuronal cells.Cell cycle (Georgetown, Tex.) · 2015Article
- Article
- Expression of integrin alpha 10 is transcriptionally activated by pRb in mouse osteoblasts and is downregulated in multiple solid tumors.Cell death & disease · 2013Article
- E2F transcription factors and digestive system malignancies: how much do we know?World journal of gastroenterology · 2013Review
- Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions.The Journal of biological chemistry · 2012Article
- E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.Genes, chromosomes & cancer · 2012Article
- miR-210: the master hypoxamir.Microcirculation (New York, N.Y. : 1994) · 2012Review
- Curcumin Induces Downregulation of E2F4 Expression and Apoptotic Cell Death in HCT116 Human Colon Cancer Cells; Involvement of Reactive Oxygen Species.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2010Article
- MiR-210--micromanager of the hypoxia pathway.Trends in molecular medicine · 2010Review
- Role of microRNA-23b in flow-regulation of Rb phosphorylation and endothelial cell growth.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- The p107/E2F pathway regulates fibroblast growth factor 2 responsiveness in neural precursor cells.Molecular and cellular biology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
We have identified a novel form of the full-length E2F-3 protein that we term E2F-3B. In contrast to full-length E2F-3, which is expressed only at the G1/S boundary, E2F-3B is detected throughout the cell cycle with peak levels in GO where it is associated with Rb. Transfection and in vitro translation experiments demonstrate that a protein identical to E2F-3B in size and iso-electric point is produced from the E2F-3 mRNA via the use of an alternative translational start site. This alternative initiation codon was mapped by mutagenesis to codon 102, an ACG codon. Mutation of the ACG codon at position 102 abolished E2F-3B expression, whereas the conversion of ACG 102 to a consensus ATG led to the expression of a protein indistinguishable from E2F-3B. Given these results, E2F-3B is missing 101 N-terminal amino acids relative to full-length E2F-3. This region includes a moderately conserved sequence of unknown function that is present only in the growth-promoting E2F family members, including E2F-1, 2 and full-length E2F-3. These observations make E2F-3B the first example of an E2F gene giving rise to two different protein species and also suggest that E2F-3 and E2F-3B may have opposing roles in cell cycle control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.